Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Self-reported Medication Adherence and CKD Progression.

Cedillo-Couvert EA, Ricardo AC, Chen J, Cohan J, Fischer MJ, Krousel-Wood M, Kusek JW, Lederer S, Lustigova E, Ojo A, Porter AC, Sharp LK, Sondheimer J, Diamantidis C, Wang X, Roy J, Lash JP; CRIC Study Investigators.

Kidney Int Rep. 2018 Feb 2;3(3):645-651. doi: 10.1016/j.ekir.2018.01.007. eCollection 2018 May.

2.

Facilitating primary care provider use in a patient-centered medical home intervention study for chronic hemodialysis patients.

Chukwudozie IB, Fitzgibbon ML, Schiffer L, Berbaum M, Gilmartin C, David P, Ekpo E, Fischer MJ, Porter AC, Aziz-Bradley A, Hynes DM.

Transl Behav Med. 2018 May 23;8(3):341-350. doi: 10.1093/tbm/iby021.

PMID:
29800412
3.

The unique associations of self-criticism and shame-proneness to symptoms of disordered eating and depression.

Porter AC, Zelkowitz RL, Cole DA.

Eat Behav. 2018 Apr;29:64-67. doi: 10.1016/j.eatbeh.2018.02.008. Epub 2018 Mar 3.

PMID:
29524786
4.

Preclinical biomarker qualification.

Sauer JM, Porter AC; Biomarker Programs, Predictive Safety Testing Consortium.

Exp Biol Med (Maywood). 2018 Feb;243(3):222-227. doi: 10.1177/1535370217743949. Epub 2017 Nov 24.

PMID:
29171289
5.

Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT).

Rocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB, Wall BM, Umanath K, Rahbari-Oskoui F, Porter AC, Pisoni R, Lewis CE, Lewis JB, Lash JP, Katz LA, Hawfield AT, Haley WE, Freedman BI, Dwyer JP, Drawz PE, Dobre M, Cheung AK, Campbell RC, Bhatt U, Beddhu S, Kimmel PL, Reboussin DM, Chertow GM; SPRINT Research Group.

Am J Kidney Dis. 2018 Mar;71(3):352-361. doi: 10.1053/j.ajkd.2017.08.021. Epub 2017 Nov 20.

PMID:
29162340
6.

Social exposure and emotion dysregulation: Main effects in relation to nonsuicidal self-injury.

Zelkowitz RL, Porter AC, Heiman ER, Cole DA.

J Adolesc. 2017 Oct;60:94-103. doi: 10.1016/j.adolescence.2017.07.015. Epub 2017 Aug 8.

PMID:
28800438
7.

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.

Kozuki T, Chikamori K, Surleac MD, Micluta MA, Petrescu AJ, Norris EJ, Elson P, Hoeltge GA, Grabowski DR, Porter ACG, Ganapathi RN, Ganapathi MK.

Nucleic Acids Res. 2017 Jun 2;45(10):5995-6010. doi: 10.1093/nar/gkx325.

8.

Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Grams ME, Yang W, Rebholz CM, Wang X, Porter AC, Inker LA, Horwitz E, Sondheimer JH, Hamm LL, He J, Weir MR, Jaar BG, Shafi T, Appel LJ, Hsu CY; CRIC Study Investigators.

Am J Kidney Dis. 2017 Sep;70(3):337-346. doi: 10.1053/j.ajkd.2017.01.050. Epub 2017 Mar 30.

PMID:
28366517
9.

Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease.

Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, Zhang X, Roy JA, Lustigova E, Nessel L, Ford V, Raj D, Porter AC, Soliman EZ, Wright JT Jr, Wolf M, He J; CRIC Investigators.

JAMA Cardiol. 2017 Jun 1;2(6):635-643. doi: 10.1001/jamacardio.2017.0363.

10.

Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.

Beck D, Zobel J, Barber R, Evans S, Lezina L, Allchin RL, Blades M, Elliott R, Lord CJ, Ashworth A, Porter AC, Wagner SD.

J Biol Chem. 2016 Aug 5;291(32):16686-98. doi: 10.1074/jbc.M116.736868. Epub 2016 Jun 6.

11.

Predictors and Outcomes of Health-Related Quality of Life in Adults with CKD.

Porter AC, Lash JP, Xie D, Pan Q, DeLuca J, Kanthety R, Kusek JW, Lora CM, Nessel L, Ricardo AC, Wright Nunes J, Fischer MJ; CRIC Study Investigators.

Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1154-62. doi: 10.2215/CJN.09990915. Epub 2016 May 31.

12.

Patient and Other Stakeholder Engagement in Patient-Centered Outcomes Research Institute Funded Studies of Patients with Kidney Diseases.

Cukor D, Cohen LM, Cope EL, Ghahramani N, Hedayati SS, Hynes DM, Shah VO, Tentori F, Unruh M, Bobelu J, Cohen S, Dember LM, Faber T, Fischer MJ, Gallardo R, Germain MJ, Ghahate D, Grote N, Hartwell L, Heagerty P, Kimmel PL, Kutner N, Lawson S, Marr L, Nelson RG, Porter AC, Sandy P, Struminger BB, Subramanian L, Weisbord S, Young B, Mehrotra R.

Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1703-12. doi: 10.2215/CJN.09780915. Epub 2016 May 19. Review.

13.

A role for human homologous recombination factors in suppressing microhomology-mediated end joining.

Ahrabi S, Sarkar S, Pfister SX, Pirovano G, Higgins GS, Porter AC, Humphrey TC.

Nucleic Acids Res. 2016 Jul 8;44(12):5743-57. doi: 10.1093/nar/gkw326. Epub 2016 Apr 29.

14.

Student Evaluation of Faculty Physicians: Gender Differences in Teaching Evaluations.

Morgan HK, Purkiss JA, Porter AC, Lypson ML, Santen SA, Christner JG, Grum CM, Hammoud MM.

J Womens Health (Larchmt). 2016 May;25(5):453-6. doi: 10.1089/jwh.2015.5475. Epub 2016 Mar 14.

15.

Fetal Sex Differences in Intrapartum Electronic Fetal Monitoring.

Porter AC, Triebwasser JE, Tuuli M, Caughey AB, Macones GA, Cahill AG.

Am J Perinatol. 2016 Jul;33(8):786-90. doi: 10.1055/s-0036-1572531. Epub 2016 Feb 23.

PMID:
26906183
16.

Use of the HPRT gene to study nuclease-induced DNA double-strand break repair.

Gravells P, Ahrabi S, Vangala RK, Tomita K, Brash JT, Brustle LA, Chung C, Hong JM, Kaloudi A, Humphrey TC, Porter AC.

Hum Mol Genet. 2015 Dec 15;24(24):7097-110. doi: 10.1093/hmg/ddv409. Epub 2015 Sep 30.

17.

Rationale and design of a patient-centered medical home intervention for patients with end-stage renal disease on hemodialysis.

Porter AC, Fitzgibbon ML, Fischer MJ, Gallardo R, Berbaum ML, Lash JP, Castillo S, Schiffer L, Sharp LK, Tulley J, Arruda JA, Hynes DM.

Contemp Clin Trials. 2015 May;42:1-8. doi: 10.1016/j.cct.2015.02.006. Epub 2015 Feb 28.

18.

Healthy lifestyle and risk of kidney disease progression, atherosclerotic events, and death in CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study.

Ricardo AC, Anderson CA, Yang W, Zhang X, Fischer MJ, Dember LM, Fink JC, Frydrych A, Jensvold NG, Lustigova E, Nessel LC, Porter AC, Rahman M, Wright Nunes JA, Daviglus ML, Lash JP; CRIC Study Investigators.

Am J Kidney Dis. 2015 Mar;65(3):412-24. doi: 10.1053/j.ajkd.2014.09.016. Epub 2014 Nov 20.

19.

Stimulation of oligonucleotide-directed gene correction by Redβ expression and MSH2 depletion in human HT1080 cells.

Xu K, Stewart AF, Porter AC.

Mol Cells. 2015 Jan 31;38(1):33-9. doi: 10.14348/molcells.2015.2163. Epub 2014 Nov 26.

20.

Urinary creatinine excretion, bioelectrical impedance analysis, and clinical outcomes in patients with CKD: the CRIC study.

Wilson FP, Xie D, Anderson AH, Leonard MB, Reese PP, Delafontaine P, Horwitz E, Kallem R, Navaneethan S, Ojo A, Porter AC, Sondheimer JH, Sweeney HL, Townsend RR, Feldman HI; CRIC Study Investigators.

Clin J Am Soc Nephrol. 2014 Dec 5;9(12):2095-103. doi: 10.2215/CJN.03790414. Epub 2014 Nov 7.

21.

SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability.

Pfister SX, Ahrabi S, Zalmas LP, Sarkar S, Aymard F, Bachrati CZ, Helleday T, Legube G, La Thangue NB, Porter AC, Humphrey TC.

Cell Rep. 2014 Jun 26;7(6):2006-18. doi: 10.1016/j.celrep.2014.05.026. Epub 2014 Jun 12.

22.

Nuclease-stimulated homologous recombination at the human β-globin gene.

Vannocci T, Kurata H, de la Fuente J, Roberts IA, Porter AC.

J Gene Med. 2014 Jan-Feb;16(1-2):1-10. doi: 10.1002/jgm.2758.

PMID:
24590875
23.

The α isoform of topoisomerase II is required for hypercompaction of mitotic chromosomes in human cells.

Farr CJ, Antoniou-Kourounioti M, Mimmack ML, Volkov A, Porter AC.

Nucleic Acids Res. 2014 Apr;42(7):4414-26. doi: 10.1093/nar/gku076. Epub 2014 Jan 29.

24.

Granzyme M targets topoisomerase II alpha to trigger cell cycle arrest and caspase-dependent apoptosis.

de Poot SA, Lai KW, van der Wal L, Plasman K, Van Damme P, Porter AC, Gevaert K, Bovenschen N.

Cell Death Differ. 2014 Mar;21(3):416-26. doi: 10.1038/cdd.2013.155. Epub 2013 Nov 1.

25.

Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.

Bhosle J, Kiakos K, Porter AC, Wu J, Makris A, Hartley JA, Hochhauser D.

Mol Cancer Ther. 2013 Dec;12(12):2897-908. doi: 10.1158/1535-7163.MCT-12-1049. Epub 2013 Oct 3.

26.

Treatment of depression and poor mental health among patients receiving maintenance dialysis: are there options other than a pill or a couch?

Fischer MJ, Porter AC, Lash JP.

Am J Kidney Dis. 2013 May;61(5):694-7. doi: 10.1053/j.ajkd.2013.02.347. No abstract available.

27.

Chemical genetic analyses of quantitative changes in Cdk1 activity during the human cell cycle.

Gravells P, Tomita K, Booth A, Poznansky J, Porter AC.

Hum Mol Genet. 2013 Jul 15;22(14):2842-51. doi: 10.1093/hmg/ddt133. Epub 2013 Mar 21.

PMID:
23525902
28.

Topoisomerase IIα promotes activation of RNA polymerase I transcription by facilitating pre-initiation complex formation.

Ray S, Panova T, Miller G, Volkov A, Porter AC, Russell J, Panov KI, Zomerdijk JC.

Nat Commun. 2013;4:1598. doi: 10.1038/ncomms2599.

29.

Ataxia telangiectasia mutated-dependent regulation of topoisomerase II alpha expression and sensitivity to topoisomerase II inhibitor.

Tamaichi H, Sato M, Porter AC, Shimizu T, Mizutani S, Takagi M.

Cancer Sci. 2013 Feb;104(2):178-84. doi: 10.1111/cas.12067. Epub 2013 Jan 13.

30.

GTPγS Binding Assays.

DeLapp NW, Gough WH, Kahl SD, Porter AC, Wiernicki TR.

In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 May 1 [updated 2012 Oct 1].

31.

Plant protein intake is associated with fibroblast growth factor 23 and serum bicarbonate levels in patients with chronic kidney disease: the Chronic Renal Insufficiency Cohort study.

Scialla JJ, Appel LJ, Wolf M, Yang W, Zhang X, Sozio SM, Miller ER 3rd, Bazzano LA, Cuevas M, Glenn MJ, Lustigova E, Kallem RR, Porter AC, Townsend RR, Weir MR, Anderson CA; Chronic Renal Insufficiency Cohort-CRIC Study Group.

J Ren Nutr. 2012 Jul;22(4):379-388.e1. doi: 10.1053/j.jrn.2012.01.026. Epub 2012 Apr 4.

32.

Creatinine-based estimations of kidney function are unreliable in obese kidney donors.

Aggarwal N, Porter AC, Tang IY, Becker BN, Akkina SK.

J Transplant. 2012;2012:872894. doi: 10.1155/2012/872894. Epub 2012 Jan 19.

33.

Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH).

Min X, Thibault ST, Porter AC, Gustin DJ, Carlson TJ, Xu H, Lindstrom M, Xu G, Uyeda C, Ma Z, Li Y, Kayser F, Walker NP, Wang Z.

Proc Natl Acad Sci U S A. 2011 May 3;108(18):7379-84. doi: 10.1073/pnas.1016167108. Epub 2011 Apr 18.

34.

Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.

Gustin DJ, Ma Z, Min X, Li Y, Hedberg C, Guimaraes C, Porter AC, Lindstrom M, Lester-Zeiner D, Xu G, Carlson TJ, Xiao S, Meleza C, Connors R, Wang Z, Kayser F.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2492-6. doi: 10.1016/j.bmcl.2011.02.052. Epub 2011 Feb 17.

PMID:
21392988
35.

Health-related quality of life in hypertension, chronic kidney disease, and coexistent chronic health conditions.

Soni RK, Porter AC, Lash JP, Unruh ML.

Adv Chronic Kidney Dis. 2010 Jul;17(4):e17-26. doi: 10.1053/j.ackd.2010.04.002. Review.

36.

Health-related quality of life in Hispanics with chronic kidney disease.

Porter AC, Vijil JC Jr, Unruh M, Lora C, Lash JP.

Transl Res. 2010 Apr;155(4):157-63. doi: 10.1016/j.trsl.2009.10.005. Epub 2009 Nov 14. Review.

37.

ZEB1 and CtBP form a repressive complex at a distal promoter element of the BCL6 locus.

Papadopoulou V, Postigo A, Sánchez-Tilló E, Porter AC, Wagner SD.

Biochem J. 2010 Apr 14;427(3):541-50. doi: 10.1042/BJ20091578.

PMID:
20175752
38.

Depletion and mutation of topoisomerase II in animal cells.

Porter AC.

Methods Mol Biol. 2009;582:245-63. doi: 10.1007/978-1-60761-340-4_19.

PMID:
19763955
39.

Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.

Yan T, Deng S, Metzger A, Gödtel-Armbrust U, Porter AC, Wojnowski L.

Mol Cancer Ther. 2009 May;8(5):1075-85. doi: 10.1158/1535-7163.MCT-09-0139. Epub 2009 May 5.

40.

Impaired telomerase activity in human cells expressing GFP-Ku86 fusion proteins.

Badie C, Yáñez-Muñoz RJ, Muller C, Salles B, Porter AC.

Cytogenet Genome Res. 2008;122(3-4):326-35. doi: 10.1159/000167819. Epub 2009 Jan 30.

PMID:
19188702
41.

Adenovirus-based targeting in myoblasts is hampered by nonhomologous vector integration.

Isman O, Roberts ML, Morgan JE, Graham IR, Goldring K, Lawrence-Watt DJ, Lu QL, Dunckley MG, Porter AC, Partridge TA, Dickson G.

Hum Gene Ther. 2008 Oct;19(10):1000-8. doi: 10.1089/hum.2008.063.

PMID:
18788904
42.

SUMO-2/3 modification and binding regulate the association of CENP-E with kinetochores and progression through mitosis.

Zhang XD, Goeres J, Zhang H, Yen TJ, Porter AC, Matunis MJ.

Mol Cell. 2008 Mar 28;29(6):729-41. doi: 10.1016/j.molcel.2008.01.013.

43.

Preventing DNA over-replication: a Cdk perspective.

Porter AC.

Cell Div. 2008 Jan 22;3:3. doi: 10.1186/1747-1028-3-3.

44.

The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049.

Bridewell DJ, Porter AC, Finlay GJ, Baguley BC.

Cancer Chemother Pharmacol. 2008 Oct;62(5):753-62. doi: 10.1007/s00280-007-0660-z. Epub 2008 Jan 3.

45.

Depletion of topoisomerase IIalpha leads to shortening of the metaphase interkinetochore distance and abnormal persistence of PICH-coated anaphase threads.

Spence JM, Phua HH, Mills W, Carpenter AJ, Porter AC, Farr CJ.

J Cell Sci. 2007 Nov 15;120(Pt 22):3952-64. Epub 2007 Oct 23.

46.

Economic factors affecting head and neck reconstructive microsurgery: the surgeons' and hospital's perspective.

Deleyiannis FW, Porter AC.

Plast Reconstr Surg. 2007 Jul;120(1):157-65.

PMID:
17572558
47.

C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo.

Linka RM, Porter AC, Volkov A, Mielke C, Boege F, Christensen MO.

Nucleic Acids Res. 2007;35(11):3810-22. Epub 2007 May 25.

49.

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews.

Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter LM.

BMC Med Res Methodol. 2007 Feb 15;7:10.

50.

Rescue of a human cell line from endogenous Cdk1 depletion by Cdk1 lacking inhibitory phosphorylation sites.

Gupta M, Trott D, Porter AC.

J Biol Chem. 2007 Feb 16;282(7):4301-9. Epub 2006 Dec 12.

Supplemental Content

Loading ...
Support Center